EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged

Amy S Paller, Elaine C Siegfried, Ashish Bansal, Jing Xiao, Faisal A Khokhar, Michael Van Spall, Xia Liu, Christine Xu, Ariane Dubost-Brama, Matthew P Kosloski iD

British Journal of Clinical Pharmacology · 04.11.2026

DOI: 10.1002/bcp.70895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 04.11.2026. Verfasst von Amy S Paller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals Inc., Sanofi, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

For children with atopic dermatitis (AD), dupilumab is available as a prefilled syringe (PFS) from the age of 6 months and as a prefilled pen (PFP) for patients aged ≥2 years, in 200‐ and 300‐mg devices. This substudy of an ongoing open‐label extension study evaluated the pharmacokinetics, efficacy and safety of switching from a dupilumab PFS device to a PFP device in children aged 2–11 years with AD.

Methods

Patients received 200 mg of dupilumab every 2 weeks (q2w, Cohort 1B) or 300 mg of dupilumab every 4 weeks (q4w, Cohorts 1A and 2B) based on age (2–5 or 6–11 years) and weight (15–

Schlagwörter

Stichwörter der Autor:innen

atopic dermatitisautoinjectordupilumabprefilled penprefilled syringe

Autor:innen und Institutionen

  • Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Division of Dermatology, Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.
  • Department of Pediatrics, Saint Louis University, St. Louis, Missouri, USA.
  • Department of Pediatric Dermatology, Cardinal Glennon Children's Hospital, St. Louis, Missouri, USA.
  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
  • Sanofi, Cambridge, Massachusetts, USA.

ORCID-Profile: Matthew P Kosloski

Förderung

  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Regeneron Pharmaceuticals

Zitieren

APA

Paller, A. S., Siegfried, E. C., Bansal, A., Xiao, J., Khokhar, F. A., Van Spall, M., Liu, X., Xu, C., Dubost-Brama, A., & Kosloski, M. P. (2026). Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70895

Vancouver

Paller AS, Siegfried EC, Bansal A, Xiao J, Khokhar FA, Van Spall M, et al. Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70895

BibTeX
@article{Paller2026,
  author = {Paller, Amy S and Siegfried, Elaine C and Bansal, Ashish and Xiao, Jing and Khokhar, Faisal A and Van Spall, Michael and Liu, Xia and Xu, Christine and Dubost-Brama, Ariane and Kosloski, Matthew P},
  title = {Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70895}
}
Kostenlos starten →